Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 01, 2009 16:30 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Biopharma Receives Complete Response Letter From FDA on Ampligen(R) New Drug Application for Chronic Fatigue Syndrome

PHILADELPHIA, Dec. 1, 2009 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company" or "Hemispherx"), announced that it received a Complete Response Letter from the U.S. Food and...
November 16, 2009 08:45 ET | Source: Hemispherx Biopharma, Inc.

Class Action Lawsuit Against Hemispherx Biopharma is Without Merit

PHILADELPHIA, Nov. 16, 2009 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company") said the recently filed lawsuit is without merit. The lawsuit is based upon the false claim...
November 09, 2009 15:00 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Biopharma, Inc. 3rd Quarter 2009 Financial Results

PHILADELPHIA, Nov. 9, 2009 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) announced its financial results for the three months ended September 30, 2009. The net loss (including...
November 02, 2009 08:45 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Biopharma Updates Chronic Fatigue Syndrome (CFS) Treatment and Commercial Application Programs

PHILADELPHIA, Nov. 2, 2009 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company"), announced a two-prong CFS clinical mission for November and December 2009. The Company...
October 26, 2009 08:45 ET | Source: Hemispherx Biopharma, Inc.

Japanese NIH Expands Pandemic Flu Protective Potential by Ampligen(R)

PHILADELPHIA, Oct. 26, 2009 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company"), announced that the research group headed by Dr. H. Hasegawa, Chief, Laboratory of Mucosal...
October 15, 2009 08:15 ET | Source: Hemispherx Biopharma, Inc.

Japanese NIH Research Reaffirms and Expands Pandemic Flu Protection by Ampligen(R)

PHILADELPHIA, Oct. 15, 2009 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company"), announced that Dr. H. Hasegawa, Chief, Laboratory of Mucosal Vaccine Development Virus...
October 13, 2009 08:15 ET | Source: Hemispherx Biopharma, Inc.

New Infectious Retrovirus Detected in Chronic Fatigue Syndrome

PHILADELPHIA, Oct. 13, 2009 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company") announced today that the discovery of a novel retrovirus in CFS may now shed new light on the...
October 08, 2009 08:15 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx's Ampligen(R)/ Intranasal Flu Vaccine Program to be Presented At International Vaccine Workshop in Osaka

PHILADELPHIA, Oct. 8, 2009 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company"), announced that Dr. H. Hasegawa, Chief, Laboratory of Mucosal Vaccine Development Virus...
October 02, 2009 08:45 ET | Source: Hemispherx Biopharma, Inc.

Stanford University Presents New Data On Immuno-Potential of Hemispherx's Ampligen(R)

PHILADELPHIA, Oct. 2, 2009 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company"), announced that Dr. Jonathan S. Berek, Professor and Chair, Obstetrics and Gynecology,...
September 28, 2009 10:30 ET | Source: Hemispherx Biopharma, Inc.

UPDATE -- Japanese National Institute of Health to Present New Data On Hemispherx's Vaccine Enhancer

PHILADELPHIA, Sept. 28, 2009 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company"), today announced data of Dr. Hasegawa, Director, the Japanese National Institute of...